Ironwood Pharmaceuticals (IRWD) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Ironwood Pharmaceuticals (IRWD) over the past year, gaining 223.1% versus a gain of 144.9%. Nuvectis Pharma is the larger company by market cap ($657.1 million vs $639.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | NVCT |
|---|---|---|
| Share price | $3.87 | $20.13 |
| Market cap | $639.48M | $657.12M |
| 1-day change | +3.20% | -0.79% |
| YTD return | +14.84% | +166.62% |
| 1-year return | +144.94% | +223.11% |
| 5-year return | -72.55% | — |
| P/E ratio (TTM) | 5.03 | — |
| Forward P/E | 2.58 | — |
| EPS (TTM) | $0.77 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $29.28 |
| 52-week low | $1.41 | $5.55 |
| Distance from 52-week high | -33.04% | -31.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +57.62% | +75.86% |
| Average volume | 2.02M | 215.43K |
| Shares outstanding | 165.24M | 32.64M |
| Employees | 100 | 16 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed IRWD by 78.2 percentage points over the past year.
- The two companies sit in different sectors: Ironwood Pharmaceuticals in Health Care and Nuvectis Pharma in Healthcare.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
IRWD vs NVCT FAQ
Which is bigger, Ironwood Pharmaceuticals or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $657.12M compared with $639.48M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, IRWD or NVCT?
NVCT returned +223.11% over the past 12 months, compared with +144.94% for IRWD (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Nuvectis Pharma in the same industry?
No. Ironwood Pharmaceuticals is in the Health Care sector, while Nuvectis Pharma is in Healthcare.